Mycoxolamine skin solution 150ml 1%

MICOXOLAMINA * SOL CUT 150ML 1%

Therapeutic indications

Skin mycoses sustained by sensitive fungi

Dosage and method of use

The different preparations make it possible to adopt, in the opinion of the doctor, the one most suitable for the individual case. Unless otherwise prescribed, the dosage is usually as follows: Micoxolamina cream and skin emulsion The cream is particularly suitable for hairless surfaces and limited extensions. Apply 2 or 3 times a day, depending on the severity of the pathology, on the lesions and immediately surrounding areas, with a light massage. Repeat the treatment until the lesions disappear (usually 1–2 weeks). To prevent relapses, it is advisable to continue the therapy for a further 1–2 weeks. An occlusive dressing is recommended in the treatment of onychomycosis. Skin solution The cutaneous solution is particularly suitable for the treatment and prevention of pityriasis versicolor, as well as sensitive infections of the scalp, such as those from Malassetia sp., Seborrheic dermatitis and pityriasis capitis (dandruff). Apply the solution on the areas affected by the infection by performing a light massage; leave the product to act for about 3–5 minutes before rinsing. In pityriasis versicolor it is recommended to perform the treatment 1 to 3 times a day until the lesions disappear, usually for 1–2 weeks. In pityriasis capitis (dandruff) and seborrheic dermatitis of the scalp, carry out 2–3 treatments per week for 2–4 weeks. In the opinion of the physician, treatment with the cutaneous solution can be continued for an additional 1–2 weeks in order to reduce the risk of recurrence.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Side effects

Occasionally, itching and burning or skin irritation may occur, usually transient.

Special warnings

The product should not be used in ophthalmic diseases. Cyclopyroxolamine should be used with caution and under direct medical supervision: - in case of concomitant systemic antifungal treatment; - in subjects with a history of immunosuppression; - in patients with compromised immune systems, such as transplant recipients and those with HIV infection; - in diabetic subjects. The use, especially if prolonged, of drugs for topical use can give rise to sensitization phenomena. In this case it is necessary to suspend the treatment and institute suitable therapeutic measures. In the course of treatment, the hygiene measures recommended by the doctor must be strictly observed.

Pregnancy and breastfeeding

In pregnant women, during lactation and in very early childhood, the medicine should be used only in cases of real need, under the direct supervision of the doctor.

Expiration and retention

MICOXOLAMINA 1% Cream - None. MICOXOLAMINA 1% Skin emulsion - None. MICOXOLAMINA 1% Cutaneous solution - store at a temperature not exceeding 25 ° C.

Interactions with other drugs

They are not known.

Overdose

Given the characteristics of the product, there is no risk of overdose.

Active principles

MICOXOLAMINA 1% CREAM 100 g of cream contain: active ingredient Ciclopiroxolamina 1 g. MICOXOLAMINA 1% SKIN EMULSION 100 g of skin emulsion contain: active ingredient Ciclopiroxolamina 1 g. MICOXOLAMINA 1% SKIN SOLUTION 100 g of cutaneous solution contain: active ingredient Ciclopiroxolamina 1 g. For excipients, see 6.1

Excipients

CREAM: ethylene glycol and polyoxyethylene glycol palmito-stearic, glycerides of polyoxyethylene saturated fatty acids, petroleum jelly, benzoic acid, butylhydroxyanisole, purified water. SKIN EMULSION: ethylene glycol and polyoxyethylene glycol palmito-stearic, glycerides of polyoxyethylene saturated fatty acids, petroleum jelly, benzoic acid, lactic acid, butylhydroxyanisole, purified water. SKIN SOLUTION: monoethanolamine lauryl sulfate, polyethylene glycol 150 stearate, polysorbate 20, lecithindiethanolamide, sodium edetate, benzyl alcohol, perfume, lactic acid, purified water.